| Olux-E Dosages & Strengths | ||||
|---|---|---|---|---|
| Strength | Format | Route | Strength | Class |
| Olux-E 0.05% | foam | topical | 100.0 gram(s) | OTC |
Stiefel Laboratories, Inc. Appoints New President - PR Newswire (press release)
... MimyX(R); Olux(TM) (clobetasol propionate, 0.05%) Foam; Olux-E(TM) (clobetasol propionate, 0.05%) Foam; Soriatane(R) (acitretin) CK CONVENIENCE KIT(TM); ...
Fri Feb 29 14:04:32 -0500 2008
Stiefel Laboratories, Inc. Appoints New President - Biloxi Sun Herald
... MimyX(R); Olux(TM) (clobetasol propionate, 0.05%) Foam; Olux-E(TM) (clobetasol propionate, 0.05%) Foam; Soriatane(R) (acitretin) CK CONVENIENCE KIT(TM); ...
Fri Feb 29 12:08:55 -0500 2008
Stiefel Laboratories, Inc. Enters into Strategic Collaboration ... - PR Newswire (press release)
... Luxiq(R) (betamethasone valerate) Foam, 0.12%; mimyx(R); Olux(TM) (clobetasol propionate) Foam, 0.05%; Olux-E(TM) (clobetasol propionate) Foam, 0.05%; ...
Tue Nov 06 23:28:07 -0500 2007
clobetasol propionate - The propionate salt form of clobetasol, a topical synthetic corticosteroid with anti-inflammatory, anti-pruritic, and vasoconstrictive properties. Clobetasol propionate exerts its effect by binding to cytoplasmic glucocorticoid receptors and subsequently activates glucocorticoid receptor mediated gene expression. This results in synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators. Specifically, clobetasol propionate appears to induce phospholipase A2 inhibitory proteins, thereby controlling the release of the inflammatory precursor arachidonic acid from membrane phospholipids by phospholipase A2.